Table 2.
Laboratory and radiologic findings between severe and nonsevere COVID-19 patients with stroke.
| Laboratory and radiologic findings | Total (N=27) | Non-severe (N = 18) | Severe (N = 9) | p |
|---|---|---|---|---|
| Laboratory tests (reference values) | ||||
| White blood cells (4-10 × 10⁹cells per l) | 6.2±1.9 | 5.6±1.6 | 7.3±2.2 | 0.055 |
| Increased (n/N; %) a | 3/27 (11.1) | 1/18 (5.6) | 2/9 (22.2) | |
| Lymphocytes (× 10⁹ per l; normal range 1.1-3.2) | 1.1±0.6 | 1.2±0.7 | 0.7±0.4 | 0.027 |
| Decreased (n/N; %) b | 12/27 (44.4) | 7/18 (38.9) | 5/9 (55.6) | |
| Neutrophils count (× 10⁹cells per l; normal range 1.8-6.3) | 4.6±1.9 | 3.9±1.3 | 6.1±2 | 0.012 |
| Increased (n/N; %) | 5/27 (18.5) | 1/18 (5.6) | 4/9 (44.4) | |
| Haemoglobin (g/l; normal range 130.0-175.0) | 130.2±17 | 132.9±17.9 | 124.7±14.3 | 0.211 |
| Decreased (n/N; %) | 3/27 (11.1) | 1/18 (5.6) | 2/9 (22.2) | |
| Platelet count (× 10⁹ per l; normal range 125.0–350.0) | 194.8±60.5 | 198.4±59 | 187.6±66.5 | 0.685 |
| Increased (n/N; %) | 2/27 (7.4) | 1/18 (5.6) | 1/9 (11.1) | |
| Alanine aminotransferase (U/l; normal range 9.0-50.0) | 23 (17.5,30.8) | 25 (21,31) | 21 (16,25) | 0.402 |
| Increased (n/N; %) | 5/26 (19.2) | 3/17 (17.6) | 2/9 (22.2) | |
| Aspartate aminotrandferase (U/l; normal range 15.0-40.0) | 25.5 (18.5, 37.8) | 24 (17, 37) | 27 (25, 38) | 0.403 |
| Increased (n/N; %) | 6/26 (23.1) | 3/17 (17.6) | 3/9 (33.3) | |
| Lactate dehydrogenase (U/l; normal range 120.0-250.0) | 241.4±66.1 | 214.6±47.1 | 292.1±69.2 | 0.011 |
| Increased (n/N; %) | 10/26 (38.5) | 4/17 (23.5) | 6/9 (66.7) | |
| Creatine kinase (U/l; normal range 50.0-170.0) | 65 (47, 119.8) | 56 (42.9, 68) | 122 (66.9, 222) | 0.029 |
| Increased (n/N; %) | 4/26 (15.4) | 1/17 (5.9) | 3/9 (33.3) | |
| Creatine kinase MB (U/l; normal range<18) | 15.7±6.9 | 14.8±6.9 | 17.4±6.8 | 0.380 |
| Increased (n/N; %) | 1/25 (4) | 1/16 (6.3) | 0/9 (0) | |
| C-reactive protein (mg/l; normal range 0.0–5.0) | 14.5 (5.2, 46.8) | 11.9 (4.9, 16.2) | 47.7 (23.5, 50.5) | 0.029 |
| Increased (n/N; %) | 19/26 (73.1) | 10/17 (58.8) | 9/9 (100) | |
| Prothrombin time (s; normal range 10.5-13.5) | 12.6 (11.7, 13.2) | 12.4 (11.5, 13) | 12.7 (12.1, 13.9) | 0.161 |
| Increased (n/N; %) | 4/26 (15.4) | 3/17 (17.6) | 1/9 (11.1) | |
| Fibrinogen (g/l; normal range 2-4) | 3.6±1.2 | 3.4±1.2 | 4.1±0.9 | 0.128 |
| Increased (n/N; %) | 13/26 (50) | 9/17 (52.9) | 4/9 (44.4) | |
| D-dimer (µg/l; normal range 0.0-0.5) | 0.7 (0.3, 1.4) | 0.4 (0.2, 1) | 1.2 (0.7, 5.5) | 0.095 |
| Increased (n/N; %) | 14/24 (58.3) | 8/15 (53.3) | 6/9 (66.7) | |
| blood glucose (mmol/l; normal range 3.9-6.1) | 6.5 (5.2, 7.3) | 6.2 (5, 7) | 7.2 (5.3, 9.6) | 0.336 |
| Increased (n/N; %) | 14/26 (53.8) | 8/17 (47.1) | 6/9 (33.3) | |
| CT findings —no./total no. (%) | ||||
| bilateral pulmonary opacities | 23/27 (85.2) | 15/18 (83.3) | 8/9 (88.9) | 1.000 |
| Unilateral pulmonary opacities | 3/27 (11.1) | 2/18 (11.1) | 1/9 (11.1) |
Note: Data are presented with median (IQR), mean (SD), n (%), or n/N (%), where N is the total number of patients with available data. P values indicate differences between nonsevere patients and severe patients, and p < 0.05 was considered as statistically significance.
a
Increased means over the upper limit of the normal range.
b
Decreased means below the lower limit of the normal range.